Skip to content

DRMA

Dermata Therapeutics, Inc.

NASDAQ · Healthcare · Biotechnology · US

$0.83
−3.31%
Ask drillr

Income statement

MetricTTM2025202420232022
Revenue
Total Revenue—————
Cost of Revenue—————
Gross Profit—————
Operating Expenses
R&D Expense1.6M2.9M8.2M4.1M5.7M
SG&A Expense4.6M4.8M4.3M4.0M4.0M
General & Admin Expense2.5M——4.0M4.0M
Selling & Marketing Expense679.3K————
Other Expenses2.4M————
Total Operating Expenses8.6M7.8M12.5M8.0M9.7M
Cost and Expenses8.6M7.8M12.5M8.0M9.7M
Operating Income (EBIT)(8.6M)(7.8M)(12.5M)(8.0M)(9.7M)
Non-Operating
Interest Income232.4K215.0K225.8K247.2K63.6K
Interest Expense—————
Net Interest Income232.4K215.0K225.8K247.2K63.6K
Other Non-Op Income/Expense232.4K215.0K225.8K247.2K63.6K
Non-Operating Income (excl Interest)(115.2K)—(225.8K)(247.0K)—
EBT (Pre-Tax Income)(8.4M)(7.6M)(12.3M)(7.8M)(9.6M)
Income Tax Expense—————
Bottom Line
Net Income(8.4M)(7.6M)(12.3M)(7.8M)(9.6M)
Earnings from Cont. Ops(8.4M)(7.6M)(12.3M)(7.8M)(9.6M)
Earnings from Discont. Ops—————
Bottom Line Net Income(8.4M)(7.6M)(12.3M)(7.8M)(9.6M)
Per Share
Basic EPS($4.39)($8.16)($80.32)($401.80)($2,088.00)
Diluted EPS($4.39)($8.16)($80.32)($399.81)($2,088.00)
Revenue Per Share$0.00$0.00$0.00$0.00$0.00
Shares
Basic Shares Outstanding4.0M926192153000194004604
Diluted Shares Outstanding4.0M926192153000194964604
Profitability Metrics
EBITDA(8.5M)(7.8M)(12.3M)246.9K(9.7M)
D&A———8.0M—
EBIT(8.5M)(7.8M)(12.3M)(7.8M)(9.7M)

As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026